Real-world outcomes of adult patients with acute lymphoblastic leukemia treated with a modified CALGB 10102 regimen.
Acute Lymphoblastic Leukemia
Chemotherapy Treatment Regimens
Real-World Outcomes
Therapeutics
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
23
05
2022
accepted:
14
02
2023
pubmed:
2
3
2023
medline:
14
3
2023
entrez:
1
3
2023
Statut:
ppublish
Résumé
Acute lymphoblastic leukemia (ALL) is an aggressive bone marrow cancer with disparate outcomes. Data on patient outcomes in real world settings outside of clinical trials is limited. The current study reports on outcomes for 137 ALL patients who received an adult induction and consolidation regimen derived from the CALGB 10102 trial modified without alemtuzumab. Of the 137 patients, 32 were < 40 years old, 52 were between 40 and 59, and 53 were ≥ 60 years old. Overall, 109 (79.6%) patients achieved a complete remission (< 40: 96.1%, 40-59: 86.5%, and 62.3% ≥ 60 (p = 0.0002)). Progression free survival for the entire cohort was 13.5 months and by age was 19.8 months for less than 40, 23.4 months for 40 to 59 and 6.7 months for ≥ 60; p = 0.0002. Median survival was 22.1 months for the entire cohort (32.9 months for ages < 40, 26.6 months ages 40-59, 7.8 months ≥ 60, p < 0.001).
Identifiants
pubmed: 36856803
doi: 10.1007/s00277-023-05141-5
pii: 10.1007/s00277-023-05141-5
pmc: PMC10688020
mid: NIHMS1935614
doi:
Substances chimiques
Alemtuzumab
3A189DH42V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
897-906Subventions
Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197991
Pays : United States
Organisme : NIH HHS
ID : P30CA012197
Pays : United States
Organisme : NIH HHS
ID : 1R01CA197991-01A1
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Cancer. 2008 Oct 15;113(8):2097-101
pubmed: 18720356
Leuk Lymphoma. 2019 Jun;60(6):1462-1468
pubmed: 30541363
J Clin Oncol. 2018 Aug 20;36(24):2514-2523
pubmed: 29863974
J Clin Oncol. 2016 Jul 10;34(20):2380-8
pubmed: 27114587
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Br J Haematol. 2009 Feb;144(4):468-83
pubmed: 19055668
Clin Lymphoma Myeloma Leuk. 2020 Jun;20(6):e320-e327
pubmed: 32199763
Blood. 1995 Apr 15;85(8):2025-37
pubmed: 7718875
Lancet Haematol. 2023 Jan;10(1):e24-e34
pubmed: 36402146
Leuk Res. 2020 Apr;91:106334
pubmed: 32135394
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Am J Hematol. 2016 Mar;91(3):322-9
pubmed: 26701142
Leuk Lymphoma. 2021 Oct;62(10):2531-2534
pubmed: 33899667
Blood. 2019 Apr 4;133(14):1548-1559
pubmed: 30658992
Leuk Lymphoma. 2014 Sep;55(9):2211-2
pubmed: 24354683
Blood. 2009 Feb 12;113(7):1408-11
pubmed: 18974371
Blood. 2017 Mar 30;129(13):1878-1881
pubmed: 28122741
J Clin Oncol. 2022 May 10;40(14):1574-1582
pubmed: 35157496
Lancet Oncol. 2018 Feb;19(2):240-248
pubmed: 29352703
JAMA Oncol. 2018 May 1;4(5):725-734
pubmed: 29450465
Haematologica. 2020 Oct 13;106(8):2086-2094
pubmed: 33054114
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Leuk Res. 2016 Feb;41:12-20
pubmed: 26686475
Leuk Lymphoma. 2020 Jan;61(1):18-26
pubmed: 31452423